Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cybrexa Therapeutics

Request full access

A New Haven, CT-based cancer therapeutics company

New Haven, United StatesFounded 2017Biotech & Life Sciences

About Cybrexa Therapeutics

Cybrexa Therapeutics, established in 2016, is a clinical-stage biotechnology firm operating from New Haven, Connecticut. The company was co-founded by Per H. Hellsund, who serves as President and CEO, and Ranjit Bindra, MD, PhD, a physician-scientist from the Yale School of Medicine who acts as Chief Scientific Advisor. Hellsund brings a track record of executive leadership from prior technology and life science ventures, including the successful development and sale of CyVek to Bio-Techne. Bindra's background as a practicing oncologist and researcher in CNS tumors provides deep clinical and scientific expertise that directly informs the company's direction. As a privately held entity, Cybrexa has secured approximately $118 million in capital through eight funding rounds, including a $40.2M Series C in June 2022, backed by investors such as Connecticut Innovations, HighCape Capital, and Elm Street Ventures.

The company's core focus is on developing a new class of cancer therapies utilizing its proprietary alphalex™ peptide-drug conjugate (PDC) platform. This technology is designed for the targeted, intracellular delivery of potent anti-cancer agents directly into tumor cells. A key differentiator of the alphalex™ platform is its antigen-independent targeting mechanism. Instead of relying on specific protein markers on a cancer cell's surface, it leverages the universally acidic tumor microenvironment—a phenomenon known as the Warburg Effect. The platform uses a pH-Low Insertion Peptide (pHLIP®), which was developed at Yale University and the University of Rhode Island, that changes its structure in low-pH conditions. This change triggers the peptide to insert itself into the cancer cell membrane, delivering a linked cytotoxic payload directly into the cell while largely sparing healthy tissue, which exists at a normal pH. This mechanism aims to improve the therapeutic index of powerful drugs, enhancing efficacy while minimizing systemic toxicity.

Cybrexa's lead clinical candidate is CBX-12, an alphalex™ conjugate of exatecan, a highly potent topoisomerase I inhibitor. CBX-12 has completed a Phase 1 study where it demonstrated a manageable safety profile and promising anti-tumor activity across a range of advanced or metastatic solid tumors. Notably, clinical benefit was observed in patients with ovarian, breast, non-small cell lung cancer (NSCLC), and colorectal cancers. Following these results, a Phase 2 trial for CBX-12 in patients with platinum-resistant ovarian cancer was initiated in late 2024. The company is also planning further Phase 2 studies for CBX-12 as both a monotherapy and in combination with other agents for various solid tumors starting in 2025. Beyond its lead program, Cybrexa is advancing its pipeline with candidates like CBX-15, which utilizes MMAE as its payload and is expected to enter clinical trials in 2025.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
62.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Apr 2021 $25M $100M Elm Street Ventures · HighCape Partners —
SERIES B✓Equity / VC Jun 2019 $13M $54M Connecticut Innovations · HighCape Partners —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Cybrexa Therapeutics website traffic

Latest recorded traffic for Cybrexa Therapeutics is 1.2K monthly website visits, down 25% over the last three months. Cybrexa Therapeutics's team declined 15.4% over the past year.

Latest monthly visits1.2K 3-month web change-25% 1-year team growth-15.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cybrexa Therapeutics in the New Haven ecosystem

Live from Dealroom

The Cybrexa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Connecticut Innovations
  • HighCape Partners
  • Elm Street Ventures

Series B and later1 investor entered at this stage

  • Advantage Capital

Other known investors3 additional known investors

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cybrexa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cybrexa Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.